Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584411 | 0.84 | ALDH1A1 (0.39) | ADORA3KDM4EALDH1A1POLBHPGD | |
| SCHEMBL13455814 | 0.75 | — | — | |
| SCHEMBL3589472 | 0.72 | — | — | |
| SCHEMBL13424026 | 0.70 | — | — | |
| SCHEMBL3551607 | 0.69 | PIK3CA (0.44) | KDM4EALDH1A1PIK3CADGAT1SOAT1 | |
| SCHEMBL17505221 | 0.65 | CCNA2 (0.39) | ADORA3KDM4EALDH1A1POLBHPGD | |
| SCHEMBL3588423 | 0.65 | GAA (0.43) | KDM4EALDH1A1POLBHPGDCYP1A2 | |
| SCHEMBL24289261 | 0.64 | UGCG (0.41) | KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL20027160 | 0.64 | NLRP3 (0.41) | KDM4EALDH1A1POLBHPGDPIK3CA | |
| SCHEMBL1776136 | 0.64 | FAAH (0.38) | PIK3CACYP1A2KMT2AGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691842-B2 | Tricyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH LLC (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1499622-B1 | HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS BETA-LACTAMASE INHIBITORS | WYETH CORP (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080318921-A1 | Tricyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| US-20060276446-A1 | Tricyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060074064-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH (US) | 2006-04-06 | — | — | US | disclosed |
| US-7018997-B2 | Tricyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040043978-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074064-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, MGAM, PREP | ADORA3 4098/4885KDM4E 1243/4885ALDH1A1 765/4885 |
| US-20080318921-A1 | Tricyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | PGLS, MGAM, PREP | ADORA3 4098/4885KDM4E 1243/4885ALDH1A1 765/4885 |
| US-20060276446-A1 | Tricyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | PEPD, PGLS, MGAM | ADORA3 3485/4885KDM4E 651/4885ALDH1A1 920/4885 |
| US-20040043978-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, MGAM, PREP | ADORA3 4213/4885KDM4E 1360/4885ALDH1A1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.